<DOC>
	<DOCNO>NCT01711112</DOCNO>
	<brief_summary>Based previous clinical experience cancer , consider absence current standard salvage regimen , single agent docetaxel select regimen phase II study . Main toxicity docetaxel myelosuppression . The low rate severe myelosuppression observe cancer trial warrant study urothelial cancer . The objective study evaluate safety activity weekly docetaxel give salvage therapy advance urothelial cancer .</brief_summary>
	<brief_title>Salvage Docetaxel Pretreated Urothelial Cancer</brief_title>
	<detailed_description>Study scheme Patients eligible study offer participation . Screening number endow subject sign inform consent form . These screen number use 'Subject Identification Code '' along subject initial . Subjects withdraw study retain screen number . Patients study drug discontinue time progression remain study 4-week safety follow-up . Those without progression may continue receive docetaxel long consider interest physician . After progression , patient remain study purpose collect follow-up survival information . VII-3 . Study treatment The study drug dos calculate take body surface area consideration . Docetaxel 30 mg/m2 administer day 1 8 every 3 week . Docetaxel dilute 250 ml 0.9 % saline 5 % dextrose produce final solution concentration 0.3-0.74 mg/ml . It administer infusion 60 min infusion day . Patients premedicated iv dexamethasone 15 mg , antihistamine prophylactic antiemetic treatment prior docetaxel infusion order reduce incidence severity fluid retention well severity hypersensitivity reaction . Patients experience adverse event attribute irinotecan treatment delay need and/or may interrupt reduce depend individual tolerability accord protocol . Treatment continue disease progression , unacceptable toxicity , consent withdrawal . After failure study treatment , treatment administer discretion investigator .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>age 20 year old histologically confirm metastatic and/or unresectable urothelial carcinoma arise bladder , ureter , renal pelvis ECOG performance status 0 1 measurable disease , evaluable lesion ( ) , define RECIST clinical failure prior chemotherapy advanced disease , include gemcitabine platinum adequate major organ function write informed consent severe comorbid illness and/or active infection prior treatment taxanes ( paclitaxel docetaxel ) patient judge investigator unfit participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>